Top Indian Growth Stocks With High Insider Ownership For October 2024
Reviewed by Simply Wall St
Over the past week, the Indian market has remained flat, yet it has experienced a remarkable 45% rise over the last year with earnings projected to grow by 17% annually. In this context, identifying growth stocks with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business in its future potential.
Top 10 Growth Companies With High Insider Ownership In India
| Name | Insider Ownership | Earnings Growth |
| Archean Chemical Industries (NSEI:ACI) | 22.9% | 34.2% |
| Kirloskar Pneumatic (BSE:505283) | 30.3% | 30.1% |
| Jupiter Wagons (NSEI:JWL) | 10.8% | 27.4% |
| Dixon Technologies (India) (NSEI:DIXON) | 24.6% | 31.6% |
| Happiest Minds Technologies (NSEI:HAPPSTMNDS) | 32.5% | 22.2% |
| Paisalo Digital (BSE:532900) | 16.3% | 24.8% |
| Apollo Hospitals Enterprise (NSEI:APOLLOHOSP) | 10.4% | 32.2% |
| Rajratan Global Wire (BSE:517522) | 19.8% | 35.8% |
| Pricol (NSEI:PRICOLLTD) | 25.5% | 24% |
| Aether Industries (NSEI:AETHER) | 31.1% | 45.9% |
Let's uncover some gems from our specialized screener.
MedPlus Health Services (NSEI:MEDPLUS)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: MedPlus Health Services Limited operates in India as a retail trader of medicines and general items, with a market cap of ₹79.49 billion.
Operations: The company's revenue is primarily derived from its retail segment, which accounts for ₹57.43 billion, supplemented by its diagnostics segment contributing ₹852.29 million.
Insider Ownership: 13.5%
Earnings Growth Forecast: 41.8% p.a.
MedPlus Health Services shows promising growth potential with earnings forecast to grow significantly at 41.8% annually, outpacing the Indian market's average. Despite recent executive changes, including the resignation of a director linked to an investor divestment, insider ownership remains influential. The company's revenue is expected to increase by 16.7% per year, surpassing the broader market's growth rate. However, interest payments are not well covered by earnings and return on equity is projected to be modest at 11%.
- Click here to discover the nuances of MedPlus Health Services with our detailed analytical future growth report.
- In light of our recent valuation report, it seems possible that MedPlus Health Services is trading beyond its estimated value.
Info Edge (India) (NSEI:NAUKRI)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Info Edge (India) Limited is an online classifieds company operating in recruitment, matrimony, real estate, and education sectors both in India and internationally, with a market cap of ₹1.06 trillion.
Operations: The company's revenue is primarily derived from its Recruitment Solutions segment, which generated ₹19.05 billion, followed by the 99acres Real Estate platform with ₹3.67 billion.
Insider Ownership: 37.7%
Earnings Growth Forecast: 23.6% p.a.
Info Edge (India) is poised for substantial earnings growth at 23.6% annually, exceeding the Indian market average. Despite a recent tax demand order and significant insider selling, the company's revenue is forecast to grow by 13% per year, surpassing the broader market's rate. Recent strategic appointments aim to bolster its public policy and revenue growth strategies. The company approved a final dividend of INR 12 per share but maintains an unstable dividend track record.
- Unlock comprehensive insights into our analysis of Info Edge (India) stock in this growth report.
- Insights from our recent valuation report point to the potential overvaluation of Info Edge (India) shares in the market.
Solara Active Pharma Sciences (NSEI:SOLARA)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Solara Active Pharma Sciences Limited is engaged in the manufacturing, processing, formulation, and distribution of active pharmaceutical ingredients (API) across India and various international markets, with a market capitalization of ₹37.90 billion.
Operations: The company's revenue from active pharmaceutical ingredients (API) is ₹13 billion.
Insider Ownership: 10.4%
Earnings Growth Forecast: 107.1% p.a.
Solara Active Pharma Sciences is projected to achieve profitability within three years, with revenue growth forecasted at 12.6% annually, outpacing the Indian market's 10.1%. Despite past shareholder dilution, recent insider activity shows more buying than selling, albeit in modest amounts. The company's earnings are expected to grow significantly by over 100% per year. Solara reaffirmed its revenue guidance for fiscal 2025 between INR 14 billion and INR 15 billion amidst board changes and strategic initiatives like the employee stock option plan expansion.
- Get an in-depth perspective on Solara Active Pharma Sciences' performance by reading our analyst estimates report here.
- The valuation report we've compiled suggests that Solara Active Pharma Sciences' current price could be quite moderate.
Turning Ideas Into Actions
- Delve into our full catalog of 93 Fast Growing Indian Companies With High Insider Ownership here.
- Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
- Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.
Contemplating Other Strategies?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NSEI:SOLARA
Solara Active Pharma Sciences
Manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally.
Undervalued with reasonable growth potential.
